Viagra and Revatio are separate branded medicines built around the same active drug, sildenafil. Their core molecular pharmacology therefore comes from the same PDE5-inhibitor compound, but the two brands were developed, studied and labeled for very different clinical contexts.
In current U.S. labeling, Viagra is a sildenafil citrate tablet product indicated for erectile dysfunction. Revatio is indicated for pulmonary arterial hypertension (WHO Group I) in adults and pediatric patients 1 to 17 years old, with label language focused on exercise ability, clinical worsening and pulmonary-hemodynamic outcomes depending on patient population.
The difference extends beyond the indication name. Viagra is associated with 25 mg, 50 mg and 100 mg oral tablets, whereas Revatio has a different strength framework and includes 20 mg tablets, a 10 mg/mL oral suspension and an intravenous formulation. This page compares those product-level differences directly without treating Viagra and Revatio as different active molecules or interchangeable brand names.
Viagra and Revatio demonstrate how one active pharmaceutical ingredient can appear in more than one branded medicine. Both products rely on sildenafil for their pharmacological activity, so the difference between them does not begin with a different PDE5-inhibitor molecule.
Instead, the products diverge at the regulatory and clinical level. They have different indications, strength frameworks, formulation ranges and administration contexts because each product was evaluated for a different labeled use.
That makes Viagra versus Revatio fundamentally different from a comparison such as sildenafil versus tadalafil or sildenafil versus vardenafil. Those comparisons involve different active drugs, whereas this comparison involves two products sharing sildenafil.
| Feature | Viagra | Revatio |
|---|---|---|
| Active drug | Sildenafil | Sildenafil |
| Drug class | PDE5 inhibitor | PDE5 inhibitor |
| Primary U.S. label context | Erectile dysfunction | Pulmonary arterial hypertension |
| Product identity | Viagra brand | Revatio brand |
| Same finished product? | No | No |
At the active-drug level, Viagra and Revatio share sildenafil. The brand names do not identify two independent PDE5 inhibitors; they identify separate finished products whose pharmacological activity originates from the same active molecule.
This shared active ingredient explains why important sildenafil properties can be relevant to both brands, including PDE5 inhibition, metabolism and several class-related safety considerations. It does not mean that every instruction or label statement for one product can automatically be transferred to the other.
For the individual drug-to-brand relationships rather than the direct brand comparison, see sildenafil and Viagra and sildenafil and Revatio.
| Identity Level | Viagra | Revatio |
|---|---|---|
| Active drug | Sildenafil | Sildenafil |
| Primary molecular target | PDE5 | PDE5 |
| Brand name | Viagra | Revatio |
| Product label | Viagra-specific | Revatio-specific |
The fundamental molecular mechanism comes from sildenafil in both products. Sildenafil inhibits phosphodiesterase type 5, reducing PDE5-mediated degradation of cGMP and thereby modifying signaling in tissues where the nitric oxide-cGMP pathway is physiologically relevant.
What differs is the clinical physiological context in which that pharmacology is being used. Viagra labeling applies sildenafil pharmacology to erectile dysfunction, whereas Revatio labeling applies the same active drug to pulmonary vascular disease.
The brand name itself does not create a new receptor, enzyme target or active compound. Detailed sildenafil pharmacology belongs on sildenafil PDE5 inhibition and the sildenafil NO-cGMP pathway.
| Mechanism Feature | Viagra | Revatio |
|---|---|---|
| Active compound | Sildenafil | Sildenafil |
| Primary target | PDE5 | PDE5 |
| cGMP regulation | Relevant | Relevant |
| Separate brand-specific molecular mechanism? | No | No |
The clearest difference between Viagra and Revatio is the indication described in each current U.S. label. Viagra is indicated for the treatment of erectile dysfunction, placing the product within an as-needed sexual-function treatment context.
Revatio is indicated for pulmonary arterial hypertension, specifically WHO Group I PAH. In adults, the current label describes its role as improving exercise ability and delaying clinical worsening. Revatio therefore belongs to a chronic pulmonary-vascular-disease treatment context rather than an erectile-dysfunction product framework.
Sharing sildenafil does not make those indications interchangeable. FDA approval applies to the particular product, formulation, population and evidence supporting the labeled use. For deeper indication-specific material, see sildenafil for erectile dysfunction and sildenafil for pulmonary hypertension.
| Indication Dimension | Viagra | Revatio |
|---|---|---|
| Primary U.S. indication | Erectile dysfunction | Pulmonary arterial hypertension (WHO Group I) |
| Treatment context | Sexual-function / ED treatment | Pulmonary vascular disease treatment |
| Adult label outcome framework | Treatment of ED | Improve exercise ability and delay clinical worsening |
| Same approved indication? | No | No |
Viagra's erectile-dysfunction label is an adult treatment context. Revatio's current PAH label is broader with respect to age because it includes both adults and pediatric patients from 1 through 17 years old.
For pediatric Revatio patients able to undergo standardized exercise testing, the label describes improvement in exercise ability. For children too young to perform that testing, the labeled endpoint is pulmonary hemodynamics thought to underlie improvements in exercise.
This difference is another reason not to treat Viagra and Revatio as interchangeable packages of sildenafil. The evidence base and intended patient populations attached to the two brands are materially different even though the pharmacologically active drug is shared.
| Population Context | Viagra | Revatio |
|---|---|---|
| Adult indication | Erectile dysfunction | PAH |
| Pediatric PAH indication | No | Yes, ages 1–17 years |
| Exercise-related PAH outcomes | Not the Viagra indication framework | Part of Revatio labeling |
| Same studied population framework? | No | No |
Viagra's current branded product context is comparatively simple: it is supplied as film-coated tablets for oral use. Revatio has a broader formulation framework because PAH treatment can involve oral tablets, an oral suspension and an intravenous formulation.
Current Revatio labeling lists 20 mg tablets, an oral suspension that provides 10 mg/mL after reconstitution and an injection containing 10 mg in 12.5 mL. These dosage forms belong to the Revatio product family and its PAH treatment context rather than to the Viagra ED brand.
The broader sildenafil formulation landscape is explained on sildenafil formulations, with separate pages for sildenafil tablets, sildenafil oral suspension and sildenafil injection.
| Formulation | Viagra | Revatio |
|---|---|---|
| Oral tablet | Yes | Yes |
| Oral suspension | Not part of current Viagra product labeling | Yes |
| Intravenous injection | Not part of current Viagra product labeling | Yes |
| Multi-formulation brand framework | No | Yes |
Viagra and Revatio also illustrate why the amount of sildenafil printed on a product label has to be interpreted within the product's indication and dosage form. Current Viagra tablets are supplied in 25 mg, 50 mg and 100 mg strengths.
Revatio uses a different product framework. Its tablets contain 20 mg sildenafil, while its oral suspension is expressed as a concentration of 10 mg/mL and its intravenous product contains 10 mg in 12.5 mL. These are formulation-specific presentations rather than alternative Viagra strengths.
A milligram value by itself therefore does not make two sildenafil products interchangeable. Strength, route, formulation, indication and prescribing instructions have to be interpreted together. The broader terminology is covered on sildenafil strengths.
| Strength / Concentration Context | Viagra | Revatio |
|---|---|---|
| Tablet strengths | 25 mg, 50 mg, 100 mg | 20 mg |
| Oral suspension | Not part of current product label | 10 mg/mL after reconstitution |
| Intravenous product | Not part of current product label | 10 mg/12.5 mL |
| Can strength alone establish interchangeability? | No | No |
The prescribing frameworks differ just as clearly as the formulations. Viagra's ED labeling uses an as-needed model tied to anticipated sexual activity. That framework fits an episodic treatment context rather than continuous disease management.
Revatio belongs to an ongoing PAH treatment framework. Its oral products and, in adults, intravenous formulation are labeled around repeated treatment of pulmonary arterial hypertension rather than occasional use associated with sexual activity.
This difference should not be reduced to a comparison of how many milligrams appear on a tablet. The intended disease, treatment schedule, route and outcome framework are all different, which is why administration instructions from one brand should not be transferred to the other.
| Prescribing Dimension | Viagra | Revatio |
|---|---|---|
| General treatment model | As-needed ED treatment | Ongoing PAH treatment |
| Administration tied to sexual activity | Yes in the ED label framework | No |
| Repeated chronic-treatment context | Not the Viagra ED framework | Yes |
| Intravenous option | No | Available in adult Revatio labeling |
Because both brands contain sildenafil, the active drug's fundamental absorption, distribution, metabolism and elimination properties provide a shared pharmacokinetic foundation. Brand naming by itself does not change sildenafil into a molecule with a different intrinsic half-life or metabolic pathway.
Product-level pharmacokinetics still depend on route and formulation. An oral sildenafil tablet must undergo gastrointestinal absorption, whereas intravenous Revatio delivers sildenafil directly into systemic circulation and therefore does not have the same absorption step. An oral suspension also has a formulation context distinct from a film-coated tablet.
For that reason, it is more accurate to say that the products share sildenafil pharmacology while their complete exposure conditions can differ. General ADME and concentration-time concepts belong on sildenafil pharmacokinetics rather than being duplicated here.
| PK Dimension | Comparison Meaning |
|---|---|
| Active-drug metabolism | Shared sildenafil foundation |
| Oral absorption | Relevant to oral Viagra and oral Revatio formulations |
| IV absorption step | Not applicable to intravenous Revatio |
| Half-life | Property of sildenafil disposition rather than the brand name itself |
| Complete exposure profile | Can depend on route and formulation |
Because both products contain sildenafil, they share several active-drug safety themes. Sildenafil-related vasodilation, nitrate and riociguat contraindications, sudden vision or hearing changes and other PDE5-related considerations can therefore appear across the product family.
The complete warnings sections are nevertheless not interchangeable because Revatio is used in a different disease population and contains PAH-specific precautions. Current Revatio labeling, for example, includes warnings concerning pulmonary veno-occlusive disease and pulmonary hypertension secondary to sickle cell disease that are not part of the Viagra ED indication framework.
The safest way to interpret the comparison is to distinguish shared sildenafil pharmacology from indication-specific product warnings. General sildenafil topics are organized on sildenafil warnings, sildenafil contraindications and sildenafil drug interactions.
| Safety Layer | Viagra vs Revatio Interpretation |
|---|---|
| Sildenafil pharmacology | Creates shared safety themes |
| Nitrates | Contraindication related to sildenafil pharmacology |
| Riociguat | Contraindication related to sildenafil pharmacology |
| PAH-specific precautions | Particularly relevant to Revatio labeling |
| Complete warning sections identical? | No |
The shared active drug creates an important practical safety point: taking Viagra and Revatio together does not represent combining two unrelated therapies. It can increase total sildenafil and PDE5-inhibitor exposure.
Current Revatio prescribing information specifically advises avoiding concomitant use with Viagra or other PDE5 inhibitors. The label notes that the safety and efficacy of combining Revatio with Viagra or other PDE5 inhibitors have not been studied.
This warning reinforces the central theme of the comparison. Separate brand names do not mean separate active-drug exposure. Product-specific prescribing information remains necessary when sildenafil appears under more than one brand identity.
| Question | Label Context |
|---|---|
| Does Viagra contain sildenafil? | Yes |
| Does Revatio contain sildenafil? | Yes |
| Would taking both create exposure to the same active drug? | Yes |
| Does Revatio labeling recommend combining them? | No; concomitant use with Viagra or other PDE5 inhibitors should be avoided |
Sharing an active ingredient is only one level of pharmaceutical identity. Interchangeability also depends on the actual drug product, strength, dosage form, route, indication and labeling. Viagra and Revatio differ across several of those dimensions.
A Viagra tablet should therefore not be interpreted simply as a differently branded Revatio tablet, nor should a Revatio product be treated as an alternative Viagra presentation based only on the presence of sildenafil. The brands belong to different regulatory treatment frameworks.
This is also why strength conversion alone is not an appropriate way to interpret the relationship. Milligram amounts are embedded within different formulations and indication-specific prescribing instructions.
| Interchangeability Question | Answer |
|---|---|
| Same active drug? | Yes |
| Same indication? | No |
| Same tablet strengths? | No |
| Same formulation range? | No |
| Same administration framework? | No |
| Automatically interchangeable because both contain sildenafil? | No |
Viagra versus Revatio is not the same type of question as generic sildenafil versus Viagra. Both Viagra and Revatio are branded sildenafil products with separate indication and product-development histories, so the primary comparison is not whether one generic product is bioequivalent to a reference brand.
Bioequivalence remains an important regulatory concept when appropriate pharmaceutical products are compared, but it does not explain why Viagra and Revatio have different labeled indications or why Revatio includes dosage forms that Viagra does not.
For the actual generic-versus-reference-product framework, see sildenafil vs Viagra and sildenafil bioequivalence.
| Comparison Type | Primary Question |
|---|---|
| Viagra vs Revatio | How do two branded sildenafil products differ in indication and product context? |
| Generic sildenafil vs Viagra | How does an approved generic counterpart compare with the reference brand? |
| Bioequivalence | How similar is systemic exposure between appropriate pharmaceutical products? |
One common misunderstanding is that different brand names must represent different active medicines. Viagra and Revatio show why that assumption fails: both rely on sildenafil even though they were developed for different indications.
The opposite mistake is assuming that the shared active ingredient makes the products identical. Revatio has a different indication, includes pediatric PAH labeling, has multiple formulations and uses a different strength and administration framework.
A third source of confusion is treating product strength as though it defines the active drug. A 20 mg Revatio tablet and the different Viagra tablet strengths all contain sildenafil, but their labeled roles cannot be inferred simply by comparing the numbers printed on the products.
| Misunderstanding | Clarification |
|---|---|
| Viagra and Revatio contain different active drugs | Incorrect; both contain sildenafil |
| Same sildenafil means identical products | Incorrect; indications, formulations, strengths and labels differ |
| Revatio is simply another Viagra strength | Incorrect; it is a separate PAH product framework |
| Different indications mean different molecular mechanisms | Incorrect; the core sildenafil PDE5 mechanism is shared |
| The brands can automatically be used together because their names differ | Incorrect; Revatio labeling advises avoiding concomitant Viagra or other PDE5 inhibitors |
This page answers a direct brand-to-brand comparison question: what is shared and what differs when Viagra and Revatio both contain sildenafil? Its unique value comes from putting indication, population, formulation, strength and prescribing context side by side.
The two relationship pages answer different questions. The Viagra relationship page explains how sildenafil relates to the Viagra brand, while the Revatio relationship page explains how sildenafil relates to Revatio independently of the other brand.
Keeping those intents separate avoids repeating the same terminology on three URLs while still allowing each page to answer its own search question completely.
| User Intent | Dedicated Page |
|---|---|
| How are Viagra and Revatio different? | This comparison page |
| How does sildenafil relate to Viagra? | Sildenafil and Viagra |
| How does sildenafil relate to Revatio? | Sildenafil and Revatio |
| What uses does sildenafil have across products? | Sildenafil Uses |
The simplest accurate interpretation is that Viagra and Revatio share sildenafil but package that active drug into different regulatory products. The common PDE5 mechanism explains their pharmacological relationship, while the labels explain why the brands serve different clinical purposes.
Viagra is an ED tablet product with 25 mg, 50 mg and 100 mg strengths. Revatio is a PAH product family with a 20 mg tablet, a 10 mg/mL oral suspension and an intravenous formulation, and its current U.S. indication extends to adults and pediatric patients 1 through 17 years old.
Those differences are substantial enough that the brands should not be treated as interchangeable even though the active drug is the same. The correct comparison is therefore shared molecular identity versus different indication, patient population, formulation, strength and prescribing framework.
| Comparison Question | Interpretation |
|---|---|
| Do both contain sildenafil? | Yes |
| Do they share the same basic PDE5 mechanism? | Yes |
| Do they have the same indication? | No |
| Do they use the same strength framework? | No |
| Do they have the same formulation range? | No |
| Do they cover the same patient populations? | No |
| Can one product label be substituted for the other? | No |
| Does Revatio labeling support concomitant use with Viagra? | No; it advises avoiding the combination |
Yes. Both branded products contain sildenafil as the active drug, so their core molecular pharmacology comes from the same PDE5 inhibitor.
The main difference is product and indication context. Viagra is labeled for erectile dysfunction, while Revatio is labeled for pulmonary arterial hypertension and has a different strength, formulation and administration framework.
Yes in current U.S. labeling. Viagra is indicated for erectile dysfunction, while Revatio is indicated for pulmonary arterial hypertension (WHO Group I).
Current U.S. Revatio labeling includes pediatric patients 1 through 17 years old with pulmonary arterial hypertension, with outcome wording adapted for whether standardized exercise testing can be performed.
Current U.S. Viagra labeling lists film-coated tablets containing 25 mg, 50 mg and 100 mg of sildenafil.
Current U.S. Revatio labeling includes 20 mg oral tablets, an oral suspension providing 10 mg/mL after reconstitution and an intravenous injection containing 10 mg in 12.5 mL.
No. Their core molecular mechanism comes from sildenafil and PDE5 inhibition. Their clinical uses differ because the same active drug is applied within different product and disease contexts.
No. They differ in approved indication, strength framework, formulation range, patient population and prescribing information, so the shared active ingredient does not make the finished products interchangeable.
Current Revatio labeling advises avoiding concomitant use with Viagra or other PDE5 inhibitors because the combination has not been established as safe and effective and would increase overlapping PDE5-inhibitor exposure.
They share sildenafil as the active drug, but complete product exposure can depend on route and formulation. Oral tablets require absorption, while intravenous Revatio delivers sildenafil directly into systemic circulation.
No. Viagra and Revatio are separate branded sildenafil products. Their comparison is mainly about indication, formulation, strength and prescribing context rather than generic bioequivalence.
Regulatory approval applies to specific products, patient populations, formulations and evidence packages. The same active pharmaceutical ingredient can therefore be developed and approved in different branded products for different clinical uses.